中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
9期
1314-1316
,共3页
黄河澄%徐志渊%林连兴%罗何三%吴盛喜
黃河澄%徐誌淵%林連興%囉何三%吳盛喜
황하징%서지연%림련흥%라하삼%오성희
肺肿瘤%抗肿瘤联合化疗方案%放射疗法,适形
肺腫瘤%抗腫瘤聯閤化療方案%放射療法,適形
폐종류%항종류연합화료방안%방사요법,괄형
Lung Neoplasms%Antincoplasm combined chemotherapy protocols%Radiotherapy,Conformal
目的 比较多西他赛联合放疗和顺铂联合放疗治疗局部晚期肺癌的疗效和不良反应.方法 将98例晚期非小细胞肺癌患者随机分为两组,所有患者均给予三维适形放疗,一组(多西他赛组)放疗联合静滴多西他赛20 mg/m2周剂量,共6次；另一组(顺铂组)放疗联合静滴顺铂,每周静滴顺铂30mg/m2,共6次.两组放疗剂量均为60 ～66 GY,每次2 GY,1周5次,共5～7周.观察两组患者疗效及毒副反应.结果 多西他赛组中位生存期为17.2个月,中位局部无进展生存时间13.5个月,1、2、3年生存率分别为78.6％、35.7％和19.5％.顺铂组中位生存期为16个月,中位局部无进展生存时间16.S个月,1、2、3年生存率分别为74％、34％和20％.两组生存时间差异无统计学意义(P＞0.05).但多西他赛组胃肠道反应、晚期放疗反应较顺铂组轻.结论 多西他赛联合放疗和顺铂联合放疗治疗局部晚期肺癌疗效相当,但多西他赛联合放疗毒副反应较轻,治疗耐受性较好.
目的 比較多西他賽聯閤放療和順鉑聯閤放療治療跼部晚期肺癌的療效和不良反應.方法 將98例晚期非小細胞肺癌患者隨機分為兩組,所有患者均給予三維適形放療,一組(多西他賽組)放療聯閤靜滴多西他賽20 mg/m2週劑量,共6次；另一組(順鉑組)放療聯閤靜滴順鉑,每週靜滴順鉑30mg/m2,共6次.兩組放療劑量均為60 ～66 GY,每次2 GY,1週5次,共5～7週.觀察兩組患者療效及毒副反應.結果 多西他賽組中位生存期為17.2箇月,中位跼部無進展生存時間13.5箇月,1、2、3年生存率分彆為78.6％、35.7％和19.5％.順鉑組中位生存期為16箇月,中位跼部無進展生存時間16.S箇月,1、2、3年生存率分彆為74％、34％和20％.兩組生存時間差異無統計學意義(P＞0.05).但多西他賽組胃腸道反應、晚期放療反應較順鉑組輕.結論 多西他賽聯閤放療和順鉑聯閤放療治療跼部晚期肺癌療效相噹,但多西他賽聯閤放療毒副反應較輕,治療耐受性較好.
목적 비교다서타새연합방료화순박연합방료치료국부만기폐암적료효화불량반응.방법 장98례만기비소세포폐암환자수궤분위량조,소유환자균급여삼유괄형방료,일조(다서타새조)방료연합정적다서타새20 mg/m2주제량,공6차；령일조(순박조)방료연합정적순박,매주정적순박30mg/m2,공6차.량조방료제량균위60 ～66 GY,매차2 GY,1주5차,공5～7주.관찰량조환자료효급독부반응.결과 다서타새조중위생존기위17.2개월,중위국부무진전생존시간13.5개월,1、2、3년생존솔분별위78.6％、35.7％화19.5％.순박조중위생존기위16개월,중위국부무진전생존시간16.S개월,1、2、3년생존솔분별위74％、34％화20％.량조생존시간차이무통계학의의(P＞0.05).단다서타새조위장도반응、만기방료반응교순박조경.결론 다서타새연합방료화순박연합방료치료국부만기폐암료효상당,단다서타새연합방료독부반응교경,치료내수성교호.
Objective To evaluate the clinical effectiveness and the major toxic effect of radiotherapy combined with docetaxol and cisplatin respectively in the treatment of locally advanced non-small cell lung cancer (NSCLC).Methods 98 patients with locally advanced NSCLC were randomly divided into two groups.All of the patients were treated with 3D-CRT.One group was treated combined with docetaxel,20mg/m2,every week,totally 6 times.The other group was treated combined with cisplatin,30mg/m2,every week,totally 6 times.The total dose was 60 ～66Gy,2Gy/F,5 times each week for 5 ～7 weeks.The clinical effect and the major toxic effect between two groups were compared.Results The median survival time in group that treated with docetaxol was 17.2 months,median progression-free survival time was 13.5 months,and the 1,2 and 3-year survival rates of the patients were 78.6％,35.7％ and 19.5％ respectively.The median survival time in group that treated with cisplatin was 16 months,median progression-free survival time was 16.5 months,and the 1,2 and 3-year survival rates of the patients were 74％,34％ and 20％ respectively.The differences between two group were not stetisticelly significant( P ＞0.05 ).However,the side effect of the stomach and intestine and late radiation complication in group treated with docetaxol were slighter than those in group treated with cisplatin.Conclusion The clinical effect of radiotherapy combined with docetaxol in the treatment of locally advanced NSCLC was equal to radiotherapy combined with cisplatin.But radiotherapy combined with docetaxol has a slighter and acceptable toxic effect,which was worth the clinical application.
